{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:32:30Z","timestamp":1793928750265,"version":"4.8.0"},"reference-count":90,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BeiGene, Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient\u2019s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and other symptoms. There are several safe and effective treatment regimens for patients with WM, and the choice of therapy should be made in a personalized fashion considering the patient\u2019s symptoms, comorbidities, and genomic profile. Bruton tyrosine kinase (BTK) inhibitors are a new option to treat patients with WM. Zanubrutinib is a next-generation covalent BTK inhibitor designed to have fewer off-target effects than previous BTK inhibitors. This review summarizes the pharmacokinetic and pharmacodynamic properties of zanubrutinib as well as safety and efficacy findings. Then, it explores the health economic and outcomes research associated with the costs of treating patients with WM and the reasons why zanubrutinib may be a more cost-effective treatment option compared with ibrutinib, a first-generation BTK inhibitor. Future directions for the treatment of WM focus on the use of zanubrutinib in combination therapy. Combinations based on effective ibrutinib or acalabrutinib treatments may be effectively applied with zanubrutinib given the similar mechanism of action for these BTK inhibitors. Combination therapies could also help prevent the development of disease resistance, minimize toxicity, and support treatment regimens of finite duration.<\/jats:p>","DOI":"10.3390\/cells11203287","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:32:23Z","timestamp":1666211543000},"page":"3287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6735","authenticated-orcid":false,"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fonc.2020.01712","article-title":"Trends in incidence and mortality of Waldenstr\u00f6m macroglobulinemia: A population-based study","volume":"10","author":"Yin","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","article-title":"Incidence of Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"82","author":"Herrinton","year":"1993","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstr\u00f6m macroglobulinaemia: Presenting features and outcome in a series with 217 cases","volume":"115","author":"Montoto","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajh.23351","article-title":"Patterns of survival in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005","volume":"88","author":"Kristinsson","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hemonc.2019.05.002","article-title":"Updates in prognostication and treatment of Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"12","author":"Advani","year":"2019","journal-title":"Hematol. Oncol. Stem Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2013.02.016","article-title":"Patients with Waldenstr\u00f6m macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration","volume":"13","author":"Treon","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.14386","article-title":"MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia","volume":"180","author":"Gustine","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstr\u00f6m macroglobulinaemia: Incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.13883","article-title":"Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): A multi-institutional retrospective study","volume":"172","author":"Castillo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","article-title":"CXCR4 mutations affect presentation and outcomes in patients with Waldenstr\u00f6m macroglobulinemia: A systematic review","volume":"12","author":"Castillo","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20406207221093962","DOI":"10.1177\/20406207221093962","article-title":"Treatment paradigm in Waldenstr\u00f6m macroglobulinemia: Frontline therapy and beyond","volume":"13","author":"Zanwar","year":"2022","journal-title":"Adv. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second COVID-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_20","unstructured":"(2019). Calquence (Acalabrutinib) [Package Insert], AstraZeneca Pharmaceuticals LP."},{"key":"ref_21","unstructured":"(2021). Brukinsa (Zanubrutinib) [Package Insert], BeiGene USA."},{"key":"ref_22","unstructured":"(2019). Imbruvica (Ibrutinib) [Package Insert], Pharmacyclics LLC."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2021-154284","article-title":"Dose reductions related to adverse effects in patients with Waldenstr\u00f6m Macroglobulinemia treated with the BTK-inhibitor ibrutinib","volume":"138","author":"Sarosiek","year":"2021","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: Practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_28","first-page":"4060","article-title":"Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia","volume":"130","author":"Sharman","year":"2017","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2019-122054","article-title":"Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States","volume":"134","author":"Huntington","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (acp-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharm. Exp."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: A single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_35","unstructured":"US Food and Drug Administration (2022, February 02). FDA Approves Zanubrutinib for Waldenstr\u00f6m\u2019s Macroglobulinemia, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/17474086.2020.1851184","article-title":"Zanubrutinib for the treatment of Waldenstr\u00f6m Macroglobulinemia","volume":"13","author":"Lim","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14737140.2022.2064849","article-title":"Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia","volume":"22","author":"Sarosiek","year":"2022","journal-title":"Expert Rev. Anticancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/bcp.14707","article-title":"Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP","volume":"87","author":"Ou","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-019-04015-w","article-title":"Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton\u2019s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects","volume":"85","author":"Mu","year":"2020","journal-title":"Cancer Chemother Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cts.12948","article-title":"Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B-cell malignancies","volume":"14","author":"Ou","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: A substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/JCO.2022.40.16_suppl.7521","article-title":"ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenstr\u00f6m macroglobulinemia (WM)","volume":"40","author":"Tam","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/1078-0432.CCR-21-0539","article-title":"A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"27","author":"An","year":"2021","journal-title":"Clin Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Castillo, J.J., Yang, K., Rongzhe, L., Wang, Y., Cohen, A., Zimmerman, T.M., Zhao, Q., Gao, X., and Tang, B. (2021, January 4\u20138). Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstr\u00f6m macroglobulinemia (WM): Matching-adjusted indirect comparisons. Proceedings of the American Society of Clinical Oncology Annual Meeting, Online.","DOI":"10.1200\/JCO.2021.39.15_suppl.7559"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1080\/10428194.2018.1441409","article-title":"Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome","volume":"59","author":"Boudin","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref_50","first-page":"E17","article-title":"Efficacy of ibrutinib in the treatment of Bing-Neel syndrome","volume":"91","author":"Lemal","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.14218","article-title":"Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome","volume":"179","author":"Mason","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_52","first-page":"8573105","article-title":"A case of Bing-Neel syndrome successfully treated with ibrutinib","volume":"2018","author":"Francescone","year":"2018","journal-title":"Case Rep. Hematol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/HS9.0000000000000155","article-title":"Efficacy of zanubrutinib in the treatment of Bing-Neel syndrome","volume":"2","author":"Wong","year":"2018","journal-title":"Hemasphere"},{"key":"ref_55","unstructured":"Yang, K., Liu, S., Tang, B., and Castillo, J.J. (2021, January 18\u201321). Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstr\u00f6m macroglobulinemia in the United States. Proceedings of the AMCP Nexus 2021, Denver, CO, USA."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yang, K., Liu, S., Irwin, D., Packnett, E., Lew, C.R., Noxon, V., Tang, B., and Chanan-Khan, A. (2021). Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers. Blood, 138.","DOI":"10.1182\/blood-2021-148443"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2021-148633","article-title":"Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: Disparities and risk factors","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e18856","DOI":"10.1200\/JCO.2021.39.15_suppl.e18856","article-title":"Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstr\u00f6m macroglobulinemia in the United States","volume":"39","author":"Castillo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_59","unstructured":"Liu, S., Yang, K., Carter, J., Pham, H., Balk, M., Massoudi, M., Liu, R., Gao, X., and Tang, B. (2021, January 18\u201321). Zanubrutinib versus ibrutinib to treat adults with Waldenstr\u00f6m macroglobulinemia: A cost per response model from a payer perspective in the United States. Proceedings of the AMCP Nexus 2021, Denver, CO, USA."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"21102","DOI":"10.18632\/aging.203314","article-title":"Bortezomib enhances the anti-cancer effect of the novel Bruton\u2019s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK","volume":"13","author":"Wang","year":"2021","journal-title":"Aging"},{"key":"ref_61","unstructured":"(2021). Gazyva (Obinutuzumab) [Package Insert], Genentech, Inc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2022.40.16_suppl.7510","article-title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial","volume":"40","author":"Zinzani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2021-144336","article-title":"Zanubrutinib in combination with venetoclax for patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del (17p): Early results from arm D of the SEQUOIA (BGB-3111-304) trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.2147\/OTT.S309408","article-title":"Successful management of a patient with refractory primary central nervous system lymphoma by zanubrutinib","volume":"14","author":"Cheng","year":"2021","journal-title":"Onco. Targets"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.3324\/haematol.2017.186817","article-title":"Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Othman","year":"2018","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: Final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1200\/JCO.2022.40.16_suppl.7566","article-title":"Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenstr\u00f6m macroglobulinemia (WM): An international collaborative study","volume":"40","author":"Abeykoon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr\u00f6m macroglobulinemia","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hon.124_2629","article-title":"Phase I clinical trial of CD19-Targeted 19-28Z\/4-1BBL \u201carmored\u201d CAR T Cells in patients with relapsed or refractory NHL and CLL including Richter transformation","volume":"37","author":"Batlevi","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10428194.2019.1665668","article-title":"Chimeric antigen receptor T cells for treatment of transformed Waldenstr\u00f6m macroglobulinemia","volume":"61","author":"Bansal","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTK(Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41419-021-04353-9","article-title":"Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies","volume":"12","author":"Kapoor","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood.2021011405","article-title":"The HCK\/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.16863","article-title":"Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19","volume":"190","author":"Thibaud","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijid.2021.02.056","article-title":"The role of ibrutinib in COVID-19 hyperinflammation: A case report","volume":"105","author":"Maynard","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:07Z","timestamp":1760144227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":90,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cells11203287"],"URL":"https:\/\/doi.org\/10.3390\/cells11203287","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}